Evidence map›Paper›PMID 29231877›Full record

ArticleMolecules (Basel, Switzerland)2017

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro.

Eman Awad, Eman M Othman, Helga Stopper

Open access · goldFull text read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Genome-Protecting Compounds as Potential Geroprotectors.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Eman AwadInstitute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany. eman.awad@uni-wuerzburg.de.
Eman M OthmanInstitute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany. eman@toxi.uni-wuerzburg.de.
Helga StopperInstitute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany. stopper@toxi.uni-wuerzburg.de.
University of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is one of the major current health problems due to lifestyle changes. Before diagnosis and in the early years of disease, insulin blood levels are elevated. However, insulin generates low levels of reactive oxygen species (ROS) which are integral to the regulation of a variety of intracellular signaling pathways, but excess levels of insulin may also lead to DNA oxidation and DNA damage. Three pharmaceutical compounds, resveratrol, lovastatin and the mTOR-inhibitor RAD-001, were investigated due to their known beneficial effects. They showed protective properties against genotoxic damage and significantly reduced ROS after in vitro treatment of cultured cells with insulin. Therefore, the selected pharmaceuticals may be attractive candidates to be considered for support of DM therapy.

Indexed as

AnimalsCells, CulturedCell SurvivalDiabetes MellitusDNA DamageEpithelial CellsEverolimusHumansInsulinKidneyLovastatinRatsReactive Oxygen SpeciesResveratrolSignal TransductionStilbenesEverolimusInsulinLovastatinReactive Oxygen SpeciesResveratrolStilbenesTOR Serine-Threonine Kinasesgenomic damageinsulinlovastatinmTOR-inhibitor RAD-001resveratrol

Identifiers

PMID29231877
PMCPMC6149724
OpenAlexW2771392587

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.